Trump threatens up to 200% tariffs on generic drugs not manufactured in the United States

President Donald Trump announced that his administration will consider imposing steep tariffs on generic medicines that are imported rather than produced in the United States.

The proposed tariffs could reach as high as 200 percent, effectively doubling the cost of those drugs for U.S. consumers if manufacturers do not shift production domestically.

The move is presented as an effort to boost American drug manufacturing, but it raises concerns among pharmaceutical companies and investors about potential price increases and supply chain disruptions.